A New Prodrug Strategy Could Make Diabetes Peptide Drugs Last Longer and Need Fewer Injections

Researchers designed PEG-peptide prodrugs using three different protease-cleavable linker sequences to connect PEG to the therapeutic peptides taspoglutide (GLP-1 analog), amylin, and pramlintide (amylin analog). They measured release kinetics and stability in mouse serum, tracking both the rate of active peptide release and the degree of peptide degradation over time.

Current GLP-1 and amylin-based drugs require daily or weekly injections, which can reduce patient adherence. A prodrug technology that protects these peptides from degradation while providing controlled release could dramatically extend dosing intervals. Less frequent injections would improve quality of life for millions of diabetes and obesity patients.

The push to create longer-acting peptide therapeutics is a major theme in diabetes and obesity drug development. While weekly GLP-1 drugs like semaglutide have been commercially successful, once-monthly or less frequent dosing remains a goal. This PEG-prodrug approach offers a modular platform that could be applied to various therapeutic peptides beyond just GLP-1 and amylin, potentially transforming how peptide drugs are formulated and delivered.

The study was conducted in mouse serum in vitro, not in living animals or humans. In vivo pharmacokinetics, efficacy, and safety have not been tested. PEG conjugation can sometimes trigger immune responses (anti-PEG antibodies) with repeated dosing, which was not addressed. The actual achievability of once-monthly dosing is speculative and would require extensive further development and formulation optimization.